Ferroptosis: key regulatory pathways and their implications in cardiovascular pathophysiology

Cardiovascular diseases (CVDs) remain a leading global health burden, necessitating novel insights into their pathogenesis and therapeutic strategies. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has emerged as a pivotal mechanism in CVD progression. This review comprehensively synthesizes current knowledge on the molecular drivers of ferroptosis, including dysregulated iron metabolism, glutathione peroxidase 4 (GPX4) inactivation, and redox imbalance orchestrated by Nrf2, AMPK, and p53. Subcellular organelles such as mitochondria, lysosomes, and the endoplasmic reticulum are highlighted as critical hubs for initiating or amplifying ferroptotic signals through oxidative stress, metabolic dysfunction, and organelle-specific interactions. The role of ferroptosis in major cardiovascular pathologies-atherosclerosis, vascular calcification, heart failure, ischemia-reperfusion injury, and arrhythmias-is systematically explored, emphasizing its contribution to cellular damage, inflammation, and tissue remodeling. Notably, this review incorporates discussions on spatial metabolomics as a powerful analytical tool, highlighting its unique capacity to decipher region-specific metabolic alterations and spatial distribution patterns of key molecules involved in ferroptosis, thereby providing deeper insights into the spatiotemporal dynamics of ferroptotic mechanisms in CVDs. Furthermore, emerging therapeutic strategies targeting ferroptosis, including iron chelators, lipid peroxidation inhibitors, and metabolic modulators (e.g., metformin, trimetazidine), are discussed for their potential to mitigate cardiovascular damage. By bridging molecular mechanisms (enhanced by spatial metabolomics insights) to clinical applications, this review underscores ferroptosis as a promising therapeutic target, advocating for further research to translate these insights into precision interventions for CVD management.

Authors

Institutions

Publication Details

Journal
Frontiers in Cardiovascular Medicine
Published
2026-04-15
DOI
https://doi.org/10.3389/fcvm.2026.1732010
Primary Topic
Ferroptosis and cancer prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ferroptosis: key regulatory pathways and their implications in cardiovascular pathophysiology

Xiaoping Peng, Xiang Wang, Kaishen Cao
Frontiers in Cardiovascular Medicine
Ferroptosis and cancer prognosis
article

Ferroptosis: key regulatory pathways and their implications in cardiovascular pathophysiology

Xiaoping Peng, Xiang Wang, Kaishen Cao
article en

Abstract

Cardiovascular diseases (CVDs) remain a leading global health burden, necessitating novel insights into their pathogenesis and therapeutic strategies. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has emerged as a pivotal mechanism in CVD progression. This review comprehensively synthesizes current knowledge on the molecular drivers of ferroptosis, including dysregulated iron metabolism, glutathione peroxidase 4 (GPX4) inactivation, and redox imbalance orchestrated by Nrf2, AMPK, and p53. Subcellular organelles such as mitochondria, lysosomes, and the endoplasmic reticulum are highlighted as critical hubs for initiating or amplifying ferroptotic signals through oxidative stress, metabolic dysfunction, and organelle-specific interactions. The role of ferroptosis in major cardiovascular pathologies-atherosclerosis, vascular calcification, heart failure, ischemia-reperfusion injury, and arrhythmias-is systematically explored, emphasizing its contribution to cellular damage, inflammation, and tissue remodeling. Notably, this review incorporates discussions on spatial metabolomics as a powerful analytical tool, highlighting its unique capacity to decipher region-specific metabolic alterations and spatial distribution patterns of key molecules involved in ferroptosis, thereby providing deeper insights into the spatiotemporal dynamics of ferroptotic mechanisms in CVDs. Furthermore, emerging therapeutic strategies targeting ferroptosis, including iron chelators, lipid peroxidation inhibitors, and metabolic modulators (e.g., metformin, trimetazidine), are discussed for their potential to mitigate cardiovascular damage. By bridging molecular mechanisms (enhanced by spatial metabolomics insights) to clinical applications, this review underscores ferroptosis as a promising therapeutic target, advocating for further research to translate these insights into precision interventions for CVD management.

Frontiers in Cardiovascular MedicineVol. 13
Nanchang University (CN), First Affiliated Hospital of Jiangxi Medical College (CN), Reference Center Foundation for Innovative Technologies (BR), Hypertension Institute (US), First Affiliated Hospital of Nanchang University (CN)
Good health and well-being
Openalex Percentile: Top 23%
Ferroptosis and cancer prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.